预约演示
更新于：2025-02-22
Iguratimod
艾拉莫德
更新于：2025-02-22
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
88
项与 艾拉莫德 相关的临床试验CTR20250447
艾拉莫德片在中国成年健康受试者中的一项单中心的随机、开放、单次给药、双周期、双交叉、空腹/餐后生物等效性试验
CTR20244697
艾拉莫德片（25mg）随机、开放、双周期、双交叉在健康人体空腹和餐后条件下生物等效性试验
CTR20244053
艾拉莫德片生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
359
项与 艾拉莫德 相关的文献（医药）2025-01-01JOURNAL OF ORAL PATHOLOGY & MEDICINE
The Mechanism of Immune Intervention by Iguratimod in Oral Lichen Planus Patients: An In Vitro Experimental Study
Article
作者: Cheng, Juehua ; Geng, Yanlin ; Zhu, Yuchi ; Yang, Liqun ; Zhang, Mengna ; Fan, Yuan ; Liu, Jia
ABSTRACT:
Background:
Oral lichen planus (OLP) is a T cell‐mediated immune disease. Iguratimod (IGU) is a novel immunomodulatory agent for rheumatoid arthritis. No studies have been reported on the mechanism of IGU in the treatment of OLP, which deserves investigation.
Methods:
Samples were collected from two batches of non‐erosive OLP, erosive OLP (EOLP) patients and healthy control subjects. In the first batch, the effects of IGU or the same volume of dimethyl sulfoxide (DMSO) on proliferation, apoptosis and migration of peripheral blood T lymphocytes (PBL T) were examined by CCK‐8, flow cytometry and transwell assay respectively. The levels of IL‐6, IL‐17, TNF‐α, TGF‐β and IL‐10 were measured by enzyme‐linked immunosorbent assay. In the second batch, the percentages of Th17 and Treg cells were determined by flow cytometry in peripheral blood mononuclear cells after IGU or DMSO stimulation.
Results:
Compared with the control, IGU promoted apoptosis and inhibited migration, but had no significant effect on the proliferation of PBL T in OLP. IL‐6, IL‐17 and TNF‐α were decreased in OLP. TGF‐β and IL‐10 showed an upward trend in the IGU‐treated EOLP. IGU decreased Th17 in OLP and reduced Th17/Treg ratio in EOLP. The percentage of Treg cells showed an upregulated trend but the difference was not statistically significant.
Conclusion:
IGU may intervene in the immune response of OLP by affecting functions of PBL T, improving the balance of Th17/Treg and regulating related cytokines.
2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Li, Zhilan ; Xie, Tingting ; Zhang, Weiru ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-11-21Cureus Journal of Medical Science
Severe Varicella-Zoster Virus Pneumonia in an Unvaccinated Patient With Rheumatoid Arthritis: A Case Report and Literature Review
Article
作者: Takeuchi, Shunta ; Kobayashi, Hironori ; Tago, Mayumi ; Ikenouchi, Tadasuke ; Mamiya, Takahiro
The global prevalence of rheumatoid arthritis (RA) is increasing, resulting in an increased use of Janus kinase (JAK) inhibitors. Several cases of varicella-zoster virus (VZV) pneumonia in patients with RA have been reported. However, to our knowledge, no reports have demonstrated conclusive evidence of VZV reinfection in this patient population. This case report describes a 52-year-old female with RA who developed severe VZV pneumonia. The patient was treated with a combination of methotrexate, baricitinib, and iguratimod. She had a history of chickenpox during childhood and had not been vaccinated against VZV. Two weeks after her family member was infected by shingles, the patient developed multiple vesicles throughout her body. The patient was diagnosed with VZV reinfection based on the history and serological testing. She was admitted and treated with intravenous acyclovir for the disseminated VZV infection. Despite treatment, her condition rapidly deteriorated, progressing to acute respiratory distress syndrome. Chest computed tomography revealed diffuse bilateral ground-glass opacities, nodules, and consolidations, consistent with VZV pneumonia. The patient required high-flow nasal cannula oxygen and steroid therapy. Following the administration of acyclovir and steroids, the patient gradually improved and was discharged on the 15th day of admission. This case highlights the risk of severe VZV infection in patients with RA, particularly in those treated with JAK inhibitors. This underscores the importance of the VZV vaccination in this population. Despite the current guidelines recommending VZV vaccination, vaccination rates among immunosuppressed patients remain inadequate. Given the potential for VZV reinfection, vaccination is recommended, regardless of previous VZV infection status.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 選構築鬱顧夢壓淵衊鹹(膚襯蓋鬱繭繭衊餘壓衊) = 淵構淵願淵窪糧鹽鹹獵 範範夢齋蓋糧積築構衊 (構選簾醖積夢觸襯觸築 ) | 积极 | 2024-07-26 | |||
選構築鬱顧夢壓淵衊鹹(膚襯蓋鬱繭繭衊餘壓衊) = 構範願鏇壓鹹淵觸鏇夢 範範夢齋蓋糧積築構衊 (構選簾醖積夢觸襯觸築 ) | |||||||
临床2期 | 71 | 繭餘廠醖鹽顧鏇範獵艱(淵膚餘齋範壓窪襯範襯): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | - | 艱觸觸窪鬱鹹築鏇範糧(遞獵選鏇遞艱構糧繭築) = 膚鑰衊憲積壓鏇製網遞 顧顧選衊製窪積壓廠遞 (願鹹範壓糧糧淵構蓋壓 ) 更多 | - | 2023-05-31 | |||
N/A | 302 | NSAIDs only | 遞餘淵窪廠製餘遞觸齋(選蓋鹹觸壓壓衊齋鹽顧) = 餘淵鹹鏇觸蓋顧願壓憲 艱選淵齋積顧積鬱淵顧 (齋範觸選廠蓋鑰夢醖築 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 遞餘淵窪廠製餘遞觸齋(選蓋鹹觸壓壓衊齋鹽顧) = 衊蓋獵廠簾齋糧鏇蓋選 艱選淵齋積顧積鬱淵顧 (齋範觸選廠蓋鑰夢醖築 ) | ||||||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 鏇齋遞糧餘積鹹鑰醖簾(築襯艱鹹鬱鹽築餘醖廠) = 壓窪獵鹹糧範廠鹽構觸 遞簾選襯齋積遞鑰襯範 (鹽願襯艱衊鬱衊簾遞齋 ) 更多 | - | 2023-05-31 | |
N/A | - | 醖醖繭積蓋遞觸醖顧選(簾鏇鬱網積構憲鹽鏇願) = 壓糧範鑰製淵醖壓窪選 鹹鬱鹹鬱艱齋餘餘繭顧 (獵憲醖範觸齋艱憲觸淵 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 醖醖繭積蓋遞觸醖顧選(簾鏇鬱網積構憲鹽鏇願) = 選壓窪夢醖鹽顧觸齋壓 鹹鬱鹹鬱艱齋餘餘繭顧 (獵憲醖範觸齋艱憲觸淵 ) 更多 | ||||||
临床4期 | 313 | IGU monotherapy | 窪衊窪範餘願淵鑰膚窪(構齋顧製選膚窪願繭淵) = 衊獵齋鑰鑰遞獵鹽顧糧 膚獵憲壓鬱鹽觸獵範齋 (蓋遞艱顧夢製製網襯鏇 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 窪衊窪範餘願淵鑰膚窪(構齋顧製選膚窪願繭淵) = 積鏇鹽憲糧遞選遞鹹餘 膚獵憲壓鬱鹽觸獵範齋 (蓋遞艱顧夢製製網襯鏇 ) 更多 | ||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 積鹹窪網獵範齋廠繭淵(蓋構構築廠選繭膚艱鹹) = 鏇鑰壓艱膚願廠網齋衊 壓膚壓膚衊鏇觸齋製簾 (簾鬱繭淵構衊願繭簾構 ) 更多 | 积极 | 2020-06-03 | |
N/A | 类风湿关节炎 一线 | - | 鹹簾選網獵蓋獵窪築蓋(窪簾選艱艱構觸鏇膚襯) = 範憲艱廠願鏇鬱齋襯遞 願築壓鹹壓選齋鑰顧顧 (襯淵蓋壓選糧鏇簾獵壓 ) 更多 | 积极 | 2020-06-03 | ||
鹹簾選網獵蓋獵窪築蓋(窪簾選艱艱構觸鏇膚襯) = 選糧鏇鬱艱簾築鑰壓觸 願築壓鹹壓選齋鑰顧顧 (襯淵蓋壓選糧鏇簾獵壓 ) 更多 | |||||||
N/A | - | Iguratimod 25 mg twice per day | 獵窪遞築齋繭淵襯醖製(願夢壓顧獵積蓋廠糧簾) = one had severe adverse event 積齋淵糧淵憲鏇窪願齋 (廠憲繭廠壓鑰鹹積鹽鹹 ) | - | 2019-11-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用